General Information of Drug (ID: DMHA18P)

Drug Name
Lasofoxifene Drug Info
Synonyms
Oporia; 180916-16-9; rac-Lasofoxifene; CP 336156; Fablyn; UNII-337G83N988; (5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol; CHEMBL328190; 337G83N988; (-)-cis-5,6,7,8-Tetrahydro-6-phenyl-5-(p-(2-(1-pyrrolidinyl)ethoxy)phenyl)-2-naphthol; 180915-78-0; CP-336,156; LASOFOXIFENE HCL; Lasofoxifene [INN:BAN]; AC1L50OI; SCHEMBL26815; GTPL7542; CTK8F1062; BDBM20606; DTXSID50171037; GXESHMAMLJKROZ-IAPPQJPRSA-N; ZINC3918428; BCP03626; AKOS030241621; AN-3516; BCP9000842; DB06202; Oporia; Lasofoxifene [INN]; Cis-1R-(4'-pyrrolidinoethoxyphenyl)-2S-phenyl-6-hydroxy-1,2,3,4-tetrahydronaphthalene, tartrate salt; AZD9639
Indication
Disease Entry ICD 11 Status REF
Osteoporosis FB83.0 Approved [1] , [2]
Virus infection 1A24-1D9Z Discontinued in Phase 1 [3]
Cross-matching ID
PubChem CID
216416
ChEBI ID
CHEBI:135938
CAS Number
CAS 180916-16-9
TTD Drug ID
DMHA18P

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Preclinical Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Palivizumab DMQM9S0 Respiratory syncytial virus infection 1C80 Approved [5]
SAR438584 DMDMAE4 Respiratory syncytial virus infection 1C80 Phase 3 [6]
Motavizumab DMB24H7 Respiratory syncytial virus infection 1C80 Phase 3 [7]
MK-1654 DM2YNMI Respiratory syncytial virus infection 1C80 Phase 2/3 [8]
GS-5806 DMDAHL6 Respiratory syncytial virus infection 1C80 Phase 2 [9]
RV521 DMSW5XJ Respiratory syncytial virus infection 1C80 Phase 2 [10]
JNJ-53718678 DMJ1FXL Respiratory syncytial virus infection 1C80 Phase 2 [11]
MEDI-557 DM6ADMG Respiratory syncytial virus infection 1C80 Phase 1 [7]
TMC-353121 DMDSJO8 Respiratory syncytial virus infection 1C80 Preclinical [4]
CL-387626 DMA4DNX Virus infection 1A24-1D9Z Terminated [12]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Estrogen receptor (ESR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [13]
Estradiol DMUNTE3 Breast cancer 2C60-2C65 Approved [14]
Estrone DM5T6US Menopausal and postmenopausal disorder GA30 Approved [14]
Estradiol valerate DM8MC6O Hormone replacement therapy 8E01 Approved [5]
Estradiol acetate DM07U2A Hormone replacement therapy 8E01 Approved [5]
Estradiol cypionate DM27Z5T Hormone replacement therapy 8E01 Approved [5]
Ethinyl estradiol DMODJ40 Female hypogonadism GA30.6 Approved [15]
Raloxifene DMDKF3M Osteoporosis FB83.0 Approved [16]
Ospemifene DMC4GEI Dyspareunia GA12 Approved [17]
Toremifene DMQYUWG Breast cancer 2C60-2C65 Approved [18]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Estrogen receptor (ESR) TTZAYWL ESR1_HUMAN Modulator [2]
Respiratory syncytial virus protein F (RSV F) TT57ID8 FUS_HRSVA Modulator [4]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7542).
2 Pfizer. Product Development Pipeline. March 31 2009.
3 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026623)
4 Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection. Curr Opin Drug Discov Devel. 2009 Jul;12(4):479-87.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040470)
7 Motavizumab. Correction in: MAbs. 2010 Sep-Oct; 2(5): 591.
8 A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein. Nat Commun. 2019 Sep 12;10(1):4153.
9 Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study. J Med Chem. 2015 Feb 26;58(4):1630-43.
10 Discovery of Sisunatovir (RV521), an Inhibitor of Respiratory Syncytial Virus Fusion. J Med Chem. 2021 Apr 8;64(7):3658-3676.
11 Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study. J Infect Dis. 2018 Jul 24;218(5):748-756.
12 Respiratory Syncytial Virus Entry Inhibitors Targeting the F Protein. Viruses. 2013 January; 5(1): 211-225.
13 Modulators of vascular sex hormone receptors and their effects in estrogen-deficiency states associated with menopause. Recent Pat Cardiovasc Drug Discov. 2008 Nov;3(3):165-86.
14 Reprint of Are all estrogens the same Maturitas. 2008 Sep-Oct;61(1-2):195-201.
15 17alpha-Ethinylestradiol hinders nucleotide excision repair in zebrafish liver cells. Aquat Toxicol. 2009 Dec 13;95(4):273-8.
16 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 620).
17 Clinical pipeline report, company report or official report of Shionogi (2011).
18 Effect of selective estrogen receptor modulators on cell proliferation and estrogen receptor activities in normal human prostate stromal and epithe... Prostate Cancer Prostatic Dis. 2009;12(4):375-81.